HC Wainwright Issues Positive Estimate for Agenus Earnings

Agenus Inc. (NASDAQ:AGEN) – Stock analysts at HC Wainwright raised their Q4 2024 earnings estimates for shares of Agenus in a report issued on Thursday, December 5th. HC Wainwright analyst E. Bodnar now anticipates that the biotechnology company will post earnings of ($2.62) per share for the quarter, up from their previous forecast of ($2.88). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Agenus’ current full-year earnings is ($12.93) per share. HC Wainwright also issued estimates for Agenus’ Q4 2025 earnings at ($1.26) EPS, FY2025 earnings at ($6.85) EPS, FY2026 earnings at ($6.04) EPS, FY2027 earnings at ($6.45) EPS and FY2028 earnings at ($6.70) EPS.

Several other analysts also recently commented on AGEN. StockNews.com downgraded Agenus from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. B. Riley decreased their price objective on Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, August 14th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, Agenus has an average rating of “Hold” and an average price target of $10.00.

Agenus Trading Down 2.2 %

NASDAQ:AGEN opened at $3.50 on Monday. Agenus has a 12 month low of $2.50 and a 12 month high of $19.69. The stock has a market capitalization of $82.11 million, a price-to-earnings ratio of -0.31 and a beta of 1.25. The firm has a fifty day simple moving average of $3.94 and a two-hundred day simple moving average of $7.71.

Institutional Trading of Agenus

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Agenus by 13.7% during the 1st quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock valued at $19,953,000 after purchasing an additional 4,134,232 shares during the period. Geode Capital Management LLC raised its holdings in shares of Agenus by 7.1% during the third quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company’s stock valued at $2,648,000 after purchasing an additional 32,016 shares during the last quarter. State Street Corp lifted its holdings in shares of Agenus by 2.1% during the 3rd quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock valued at $2,563,000 after buying an additional 9,731 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Agenus by 52.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock valued at $208,000 after acquiring an additional 123,058 shares during the period. Finally, Walleye Capital LLC bought a new stake in shares of Agenus during the 3rd quarter valued at about $1,003,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.